Session » Infection-related Rheumatic Disease Poster
- 10:30AM-12:30PM
-
Abstract Number: 0255
“Rheum” to Improve: Have Patients Attending the Young Adult Systemic Erythematosus (YASLE) Clinic Received All Appropriate Vaccinations? A Quality Improvement Initiative
- 10:30AM-12:30PM
-
Abstract Number: 0244
Adjunctive Belimumab Exerts Favorable Ferritin Recovery and Survival for Post-COVID Interstitial Lung Disease in Patients with Immune Mediated Inflammatory Diseases Treated with Rituximab: A Case Series
- 10:30AM-12:30PM
-
Abstract Number: 0241
Anti-Spike Antibodies in SARS-CoV-2-Vaccinated SLE Patients
- 10:30AM-12:30PM
-
Abstract Number: 0256
Anti-TNF Therapy as a Potential Risk of Leishmania Infections
- 10:30AM-12:30PM
-
Abstract Number: 0262
Bartonella Endocarditis as an Important Mimic of ANCA Associated Vasculitis: Results of a Large Single Center Descriptive Analysis
- 10:30AM-12:30PM
-
Abstract Number: 0240
Cellular and Humoral Responses Following a Fifth, Updated SARS-CoV-2 Vaccine Dose and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study
- 10:30AM-12:30PM
-
Abstract Number: 0263
Characteristics and Coinfections of Diffuse Alveolar Hemorrhage in Rheumatic Patients
- 10:30AM-12:30PM
-
Abstract Number: 0261
Clinical Implications, Bacterial Profiles, and Patient Outcomes in Hospitalized Patients with Autoimmune Rheumatic Diseases
- 10:30AM-12:30PM
-
Abstract Number: 0264
Clinical Value of Metagenomic Next-generation Sequencing in Patients with Connective Tissue Disease Co-infections: A Single-center Study from Southern Hospital in China
- 10:30AM-12:30PM
-
Abstract Number: 0250
Effectiveness of Tuberculosis Preventive Treatment in Patients with Rheumatic Diseases: A Global Meta-analysis of Cohort Studies
- 10:30AM-12:30PM
-
Abstract Number: 0247
Enhanced Immunogenicity of the Recombinant Herpes Zoster Vaccine After One-Week of Mycophenolate Mofetil Discontinuation in Patients with Autoimmune Rheumatic Diseases: Interim Results from a Prospective Randomized Phase 4 Study
- 10:30AM-12:30PM
-
Abstract Number: 0257
High Prevalence of Strongyloides Antibodies in Patients at Risk for Dissemination. A Call for Action
- 10:30AM-12:30PM
-
Abstract Number: 0243
Humoral Response to SARS-CoV-2 Vaccination and Breakthrough COVID-19 Disease in Patients with Immune-mediated Inflammatory Diseases Receiving Biological Treatment
- 10:30AM-12:30PM
-
Abstract Number: 0236
Impact of Socioeconomic Status on Infection-Related Hospitalization Risk in Patients with Systemic Autoimmune Diseases
- 10:30AM-12:30PM
-
Abstract Number: 0238
Longitudinal Assessment of CD8+ T Cell Responses to SARS-CoV-2 Pre- and Post-breakthrough Infection and Its Association with COVID-19 Severity in Immunosuppressed Individuals
- 10:30AM-12:30PM
-
Abstract Number: 0260
National Survey on Patient’s Knowledge and Drivers of Human Papillomavirus (HPV) Vaccination in Immune-mediated Inflammatory Diseases (IMIDs)
- 10:30AM-12:30PM
-
Abstract Number: 0258
Nationwide Analysis of Adult Non-Gonococcal Bacterial Septic Arthritis Hospitalizations from the National Inpatient Sample 2016 to 2020
- 10:30AM-12:30PM
-
Abstract Number: 0239
Neutralising Antibody Responses to Bivalent SARS-CoV-2 Vaccines and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study
- 10:30AM-12:30PM
-
Abstract Number: 0253
Outcomes of Respiratory Syncytial Virus Infection in Patients with Systemic Autoimmune Rheumatic Diseases
- 10:30AM-12:30PM
-
Abstract Number: 0252
Prospective Study of Severe Infectious Events and Immune Reconstitution After Rituximab in Autoimmune Diseases
- 10:30AM-12:30PM
-
Abstract Number: 0249
Real World Evidence on the Safety of the Adjuvanted Recombinant Zoster Vaccine in Patients with Rheumatic Diseases – Preliminary Results from a Prospective Multicenter Observational Greek Study
- 10:30AM-12:30PM
-
Abstract Number: 0248
Recombinant Herpes Zoster Vaccine in a Large Cohort of Autoimmune Rheumatic Diseases Patients: An Interim Analysis of a Prospective Randomized Phase 4 Study
- 10:30AM-12:30PM
-
Abstract Number: 0254
Rheumatic Manifestations in Patients with Hansen’s Disease Treated with Multidrug Antibiotic Therapy
- 10:30AM-12:30PM
-
Abstract Number: 0246
Selectively Targeting TRBV11-2+ T Cells in Multisystem Inflammatory Syndrome in Children (MIS-C) Using Bispecific T Cell-Engaging Antibodies
- 10:30AM-12:30PM
-
Abstract Number: 0251
T-SPOT.TB and TST in Diagnosing Active Tuberculosis in Patients with Rheumatic Immune Diseases: A Fully Paired Comparative Diagnostic Test Accuracy Study
- 10:30AM-12:30PM
-
Abstract Number: 0245
The Impact of COVID-19 and ‘Long COVID’ on Self-Reported Disease Activity, Disability, and Quality of Life in Patients with Inflammatory Arthritis
- 10:30AM-12:30PM
-
Abstract Number: 0237
Tofacitinib: A Retrospective Study on Safety and Adverse Effects
- 10:30AM-12:30PM
-
Abstract Number: 0242
Use of Outpatient Antiviral Therapy and Severe Outcomes from SARS-CoV-2 Omicron Infection in Patients with Immune Mediated Diseases on B Cell Depleting Agents
- 10:30AM-12:30PM
-
Abstract Number: 0259
Whipple’s Disease in Patients Initially Diagnosed with Rheumatic Diseases: A Case Series